Sector News

Icon buys MediMedia Pharma Solutions for $120 million

February 2, 2015
Life sciences
Ireland-based Icon is to acquire MediMedia Pharma Solutions for $120 million, creating “the industry’s leading integrated scientific communications and market access solution”.
 
The Yardley, Pennsylvania-based company is a division of MediMedia USA and is being sold by Vestar Capital Partners. The deal includes MediMedia Managed Markets and Complete Healthcare Communications. The former provides “strategic payer-validated market access solutions”, while the latter is an agency which works with medical affairs, commercial and brand development teams within life science companies.
 
Icon chief executive Ciaran Murray said “the need to demonstrate and communicate the value of new medicines is an important global healthcare trend” and the acquisition of MediMedia Pharma Solutions “deepens the expertise” of the company’s existing operations “and brings us outstanding scientific and medical communications capabilities”.
 
The deal comes days after Icon announced plans to create 200 new jobs as part of a new global innovation hub in Ireland, with the posts split between Dublin and Limerick.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.